Safety Rates Drug Report: NEVIRAPINE. Cerebral ventricle dilatation adverse events in 2016 Q3 - FDA prescription drugs adverse events in an open, searchable, online, public database

2004.Q1 2004.Q2 2004.Q3 2004.Q4 2005.Q1 2005.Q2 2005.Q3 2005.Q4 2006.Q1 2006.Q2 2006.Q3 2006.Q4 2007.Q1 2007.Q2 2007.Q3 2007.Q4 2008.Q1 2008.Q2 2008.Q3 2008.Q4 2009.Q1 2009.Q2 2009.Q3 2009.Q4 2010.Q1 2010.Q2 2010.Q3 2010.Q4 2011.Q1 2011.Q2 2011.Q3 2011.Q4 2012.Q1 2012.Q2 2012.Q3 2012.Q4 2013.Q1 2013.Q2 2013.Q3 2013.Q4 2014.Q1 2014.Q2 2014.Q3 2014.Q4 2015.Q1 2015.Q2 2015.Q3 2015.Q4 2016.Q1 2016.Q2 2016.Q3

Drug Injury Quarter

Drug: NEVIRAPINE. Injury: Cerebral ventricle dilatation Quarter: 2016Q3

|< 1/2 << Previous Page Page 1

Total Records: 1 Number of Pages: 1

Event ID	DRUGNAME	PT	Drug Manufacturer	Patient Age	Sex	Weight	Date (YYYYMMDD)	Country
97053484	NEVIRAPINE.	Cerebral ventricle dilatation	BRISTOL MYERS SQUIBB	0.00		0	20160720	IT

|< 1/2 << Previous Page Page 1

Total Records: 1 Number of Pages: 1

Execution Time: 0.78959107398987 seconds (ucode:5094889). Developed by: James D. Barger